RXRX: Recursion Pharmaceuticals, Inc.
About
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
Current Value
$6.301 Year Return
Current Value
$6.301 Year Return
Key Details
Market Cap
$1.80B
P/E Ratio
-4.1
1Y Stock Return
-4.13%
1Y Revenue Growth
37.64%
Dividend Yield
0.00%
Price to Book
3.4
Strategies that include RXRX
Stock's related to RXRX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BEAM | 62.89% | $2.09B | -9.52% | 0.00% |
| CRSP | 58.45% | $4.01B | -30.49% | 0.00% |
| SW | 54.64% | $13.78B | +15.02% | 1.14% |
| NTLA | 54.64% | $1.44B | -50.35% | 0.00% |
| TWST | 53.68% | $2.42B | +74.27% | 0.00% |
| CNNE | 53.20% | $1.27B | +14.42% | 1.18% |
| OPEN | 51.95% | $1.14B | -31.62% | 0.00% |
| NNOX | 49.80% | $332.87M | -7.63% | 0.00% |
| DDD | 49.78% | $402.06M | -35.13% | 0.00% |
| CLSK | 49.76% | $3.65B | +211.70% | 0.00% |
| MCFT | 49.40% | $344.65M | -0.29% | 0.00% |
| SOFI | 49.13% | $15.65B | +114.58% | 0.00% |
| NMRK | 49.06% | $2.60B | +94.74% | 0.79% |
| OUT | 48.98% | $3.11B | +52.98% | 6.41% |
| RIOT | 48.66% | $4.08B | +9.85% | 0.00% |
| ABCL | 48.39% | $800.44M | -37.56% | 0.00% |
| KN | 48.33% | $1.60B | +12.19% | 0.00% |
| PGEN | 47.91% | $228.91M | -28.00% | 0.00% |
| FARO | 47.61% | $486.17M | +40.51% | 0.00% |
| DAN | 47.22% | $1.14B | -38.75% | 5.12% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PRPO | -0.04% | $9.10M | -13.65% | 0.00% |
| LPLA | 0.08% | $23.55B | +38.13% | 0.38% |
| T | -0.12% | $163.09B | +40.40% | 4.87% |
| GL | -0.14% | $9.18B | -8.60% | 0.86% |
| LNG | 0.19% | $49.37B | +24.99% | 0.82% |
| SYPR | 0.22% | $32.23M | -26.32% | 0.00% |
| CNA | 0.23% | $13.16B | +23.03% | 3.61% |
| BTCT | -0.30% | $42.61M | +353.33% | 0.00% |
| HSY | -0.34% | $34.45B | -10.68% | 3.21% |
| UNH | 0.43% | $531.00B | +6.93% | 1.37% |
| FENG | -0.47% | $13.37M | +96.77% | 0.00% |
| NEUE | 0.49% | $40.93M | -34.13% | 0.00% |
| SUZ | -0.63% | $13.00B | -2.96% | 2.27% |
| SO | 0.69% | $96.74B | +26.76% | 3.24% |
| CHE | 0.75% | $8.20B | -5.60% | 0.33% |
| THG | 0.82% | $5.88B | +36.24% | 2.08% |
| DMLP | 0.93% | $1.58B | +18.00% | 10.54% |
| CAG | -0.96% | $12.64B | -6.10% | 5.26% |
| WTW | -1.06% | $30.98B | +26.60% | 1.13% |
| AGO | 1.12% | $4.66B | +37.77% | 1.01% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -21.90% | $78.15B | +35.51% | 0.42% |
| PGR | -19.43% | $149.10B | +57.29% | 0.45% |
| CBOE | -17.57% | $21.46B | +15.84% | 1.11% |
| ACGL | -15.73% | $36.00B | +16.84% | 0.00% |
| CAH | -14.98% | $28.64B | +12.14% | 1.70% |
| COR | -14.95% | $47.48B | +21.20% | 0.86% |
| CHD | -13.49% | $27.18B | +19.50% | 1.03% |
| AJG | -12.46% | $64.17B | +17.51% | 0.80% |
| CME | -11.58% | $82.76B | +9.21% | 1.98% |
| RNR | -11.45% | $13.74B | +23.09% | 0.58% |
| LMT | -10.95% | $126.40B | +18.99% | 2.36% |
| PULM | -10.92% | $19.83M | +202.98% | 0.00% |
| CYD | -10.39% | $364.46M | -2.94% | 4.26% |
| HUSA | -10.17% | $16.69M | -11.56% | 0.00% |
| NOC | -9.80% | $71.54B | +4.23% | 1.60% |
| CHKP | -8.46% | $19.20B | +20.74% | 0.00% |
| WM | -7.75% | $87.92B | +27.58% | 1.34% |
| MNOV | -7.73% | $93.19M | +2.15% | 0.00% |
| MMC | -7.54% | $108.41B | +10.89% | 1.37% |
| TCTM | -7.12% | $8.10M | -42.99% | 0.00% |
ETF's related to RXRX
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| ARKG | 75.25% | $1.13B | 0.75% |
| GNOM | 65.60% | $70.59M | 0.5% |
| ARKK | 65.17% | $6.28B | 0.75% |
| KOMP | 64.97% | $2.09B | 0.2% |
| VBK | 62.22% | $19.31B | 0.07% |
| IWO | 62.13% | $12.56B | 0.24% |
| XBI | 61.98% | $6.58B | 0.35% |
| IWC | 61.63% | $933.99M | 0.6% |
| ISCG | 60.94% | $640.00M | 0.06% |
| IWM | 60.67% | $75.73B | 0.19% |
| RSPA | 60.66% | $273.87M | 0% |
| VXF | 60.61% | $21.54B | 0.06% |
| NUSC | 60.48% | $1.27B | 0.31% |
| VTWO | 60.39% | $12.38B | 0.1% |
| IBUY | 59.95% | $176.17M | 0.65% |
| ESML | 59.62% | $1.90B | 0.17% |
| ROBT | 59.31% | $441.35M | 0.65% |
| SMMD | 59.24% | $1.24B | 0.15% |
| PRFZ | 59.11% | $2.65B | 0.39% |
| IPO | 59.00% | $157.08M | 0.6% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CCOR | 0.08% | $109.04M | 1.18% |
| BSCO | 0.44% | $2.35B | 0.1% |
| JUCY | -0.60% | $324.29M | 0.6% |
| CSHI | 0.66% | $482.85M | 0.38% |
| FLRN | 0.71% | $2.33B | 0.15% |
| DBA | 0.76% | $755.88M | 0.93% |
| JBBB | -0.80% | $1.26B | 0.49% |
| MINT | 0.91% | $11.62B | 0.35% |
| CLOI | -0.96% | $715.40M | 0.4% |
| CANE | -1.19% | $17.72M | 0.29% |
| XHLF | 1.26% | $874.27M | 0.03% |
| TBIL | 1.77% | $4.38B | 0.15% |
| XBIL | -2.23% | $637.70M | 0.15% |
| DUSB | 2.53% | $797.63M | 0.15% |
| BILZ | -2.84% | $563.02M | 0.14% |
| CORN | -3.01% | $61.12M | 0.2% |
| SGOV | -3.18% | $27.53B | 0.09% |
| HDRO | 3.47% | $164.26M | 0.3% |
| FLTR | 3.79% | $1.79B | 0.14% |
| KRBN | 3.87% | $242.47M | 0.85% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -62.13% | $388.04M | 1.43% |
| VIXY | -31.44% | $195.31M | 0.85% |
| UUP | -30.13% | $309.25M | 0.77% |
| USDU | -29.78% | $201.97M | 0.5% |
| TAIL | -19.37% | $67.98M | 0.59% |
| AGZD | -8.87% | $142.76M | 0.23% |
| KMLM | -7.91% | $353.87M | 0.9% |
| EQLS | -7.27% | $76.08M | 1% |
| CTA | -6.98% | $350.27M | 0.78% |
| KCCA | -6.82% | $220.51M | 0.87% |
| WEAT | -6.80% | $120.27M | 0.28% |
| IBHD | -6.05% | $327.80M | 0.35% |
| SGOV | -3.18% | $27.53B | 0.09% |
| CORN | -3.01% | $61.12M | 0.2% |
| BILZ | -2.84% | $563.02M | 0.14% |
| XBIL | -2.23% | $637.70M | 0.15% |
| CANE | -1.19% | $17.72M | 0.29% |
| CLOI | -0.96% | $715.40M | 0.4% |
| JBBB | -0.80% | $1.26B | 0.49% |
| JUCY | -0.60% | $324.29M | 0.6% |
News
Yahoo
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discoveryRecursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT on LinkedIn, X and Youtube
SeekingAlpha
Recursion struggles with losses and high cash burn despite a $500M IPO. See why RXRX stock remains a "Hold" amid funding pressures and low pipeline catalysts.
Yahoo
AI kingpin Nvidia disclosed an investment in Applied Digital, a digital infrastructure solutions provider. Nvidia stock dipped while APLD stock rose.
Finnhub
Item 5.07. Submission of Matters to a Vote of Security Holders. On August 8, 2024, Recursion Pharmaceuticals, Inc. , entered into a transaction agreement with Exscientia plc, a public...
Yahoo
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated closeSalt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia. The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to
Finnhub
Recursion and Exscientia Shareholders Approve the Proposed Combination ●Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close ...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.